In February 2025, Teva Pharmaceuticals and Alvotech announced ... because of the potential risk for shedding from the household contact and transmission to patient. Non-live vaccinations received ...

This marks the second biosimilar released in the U.S. by the strategic partnership between Teva Pharmaceuticals and ... for shedding from the household contact and transmission to patient.

SELARSDI is approved for the treatment of moderate to severe plaque psoriasis and active psoriatic arthritis in adults and ...

New research by Teva Pharmaceuticals Europe shows that 46% of generic medicines from the EU Critical List of Medicines are supplied by only one provider. This ...

Regulatory ApprovalFormycon receives regulatory approval in the UK for FYB203 (aflibercept), a biosimilar to Eylea®, under the brand name AHZANTIVE® 25.02.2025 / 06:30 CET/CESTThe issuer is solely ...

Receive News & Ratings for Teva Pharmaceutical Industries Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teva Pharmaceutical ...

Receive News & Ratings for Teva Pharmaceutical Industries Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teva Pharmaceutical ...

WHY EUROPE MUST ACT TO PROTECT ACCESS TO MEDICINESAmsterdam, 20 February 2025 New research by Teva Pharmaceuticals Europe shows that 46% of generic medicines from the EU Critical List of Medicines are ...

New York, New York-- (Newsfile Corp. - February 23, 2025) - Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against ICON plc (NASDAQ: ICLR) and certain ...

New York, New York-- (Newsfile Corp. - February 23, 2025) - Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against TransMedics Group, Inc. (NASDAQ: TMDX ...

Biopharma doubles down on immunology and inflammation as companies target new pathways and seek to improve on current options ...